1-5 of 5
Radj Gervais
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non–Small Cell Lung Cancer

Sandra Ortiz-Cuaran, Laura Mezquita, Aurélie Swalduz, Mihalea Aldea, Julien Mazieres, Camille Leonce, Cecile Jovelet, Anne Pradines, Virginie Avrillon, Washington R. Chumbi Flores, Ludovic Lacroix, Yohann Loriot, Virginie Westeel, Maud Ngo-Camus, Claire Tissot, Christine Raynaud, Radj Gervais, Etienne Brain, Isabelle Monnet, Etienne Giroux Leprieur, Caroline Caramella, Celine Mahier-Aït Oukhatar, Natalie Hoog-Labouret, Frank de Kievit, Karen Howarth, Clive Morris, Emma Green, Luc Friboulet, Sylvie Chabaud, Jean-François Guichou, Maurice Perol, Benjamin Besse, Jean-Yves Blay, Pierre Saintigny, David Planchard
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6242–6253.
https://doi.org/10.1158/1078-0432.CCR-20-1037
Published: 01 December 2020
View article titled, Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <em>BRAF</em>-Mutant Metastatic Non–Small Cell Lung Cancer
Open the PDF for Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with <em>BRAF</em>-Mutant Metastatic Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial

Guillaume Eberst, Amélie Anota, Arnaud Scherpereel, Julien Mazieres, Jacques Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro-Sibilot, Olivier Molinier, Hervé Léna, Frédéric Rivière, Isabelle Monnet, Valérie Gounant, Henri Janicot, Radj Gervais, Chrystelle Locher, Emilie Charton, Franck Morin, Gérard Zalcman, Virginie Westeel
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (19): 5759–5765.
https://doi.org/10.1158/1078-0432.CCR-18-2860
Published: 01 October 2019
View article titled, Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial
Open the PDF for Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial in another window
Includes: Supplementary data
Journal Articles

Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

Benjamin Besse, Sylvestre Le Moulec, Julien Mazières, Hélène Senellart, Fabrice Barlesi, Christos Chouaid, Eric Dansin, Henri Bérard, Lionel Falchero, Radj Gervais, Gilles Robinet, Anne-Marie Ruppert, Roland Schott, Hervé Léna, Christelle Clément-Duchêne, Xavier Quantin, Pierre Jean Souquet, Jean Trédaniel, Denis Moro-Sibilot, Maurice Pérol, Anne-Catherine Madroszyk, Jean-Charles Soria
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (8): 1896–1903.
https://doi.org/10.1158/1078-0432.CCR-14-2082
Published: 14 April 2015
View article titled, Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
Open the PDF for Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study in another window
Includes: Supplementary data
Journal Articles

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002

Sébastien Couraud, Felipe Vaca-Paniagua, Stéphanie Villar, Javier Oliver, Tibor Schuster, Hélène Blanché, Nicolas Girard, Jean Trédaniel, Laurent Guilleminault, Radj Gervais, Nathalie Prim, Michel Vincent, Jacques Margery, Sébastien Larivé, Pascal Foucher, Bernard Duvert, Maxime Vallee, Florence Le Calvez-Kelm, James McKay, Pascale Missy, Franck Morin, Gérard Zalcman, Magali Olivier, Pierre-Jean Souquet
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4613–4624.
https://doi.org/10.1158/1078-0432.CCR-13-3063
Published: 01 September 2014
View article titled, Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002
Open the PDF for Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002 in another window
Includes: Supplementary data
Journal Articles

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

Carlota Costa, Miguel Angel Molina, Ana Drozdowskyj, Ana Giménez-Capitán, Jordi Bertran-Alamillo, Niki Karachaliou, Radj Gervais, Bartomeu Massuti, Jia Wei, Teresa Moran, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario Garcia-Campelo, Santiago Viteri, Miquel Taron, Mayumi Ono, Petros Giannikopoulos, Trever Bivona, Rafael Rosell
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 2001–2010.
https://doi.org/10.1158/1078-0432.CCR-13-2233
Published: 31 March 2014
View article titled, The Impact of <em>EGFR</em> T790M Mutations and <em>BIM</em> mRNA Expression on Outcome in Patients with <em>EGFR</em>-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
Open the PDF for The Impact of <em>EGFR</em> T790M Mutations and <em>BIM</em> mRNA Expression on Outcome in Patients with <em>EGFR</em>-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial in another window
Includes: Supplementary data